Advanced search
Publication Cover
OncoTargets and Therapy Volume 16, 2023 - Issue
Submit an article Journal homepage
311
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Meshaal Alanzi1 Department of Internal Medicine, Hamad Medical Corporation, Doha, QatarCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7201-7010View further author information
ORCID Icon,
Mohammad Abu-Tineh2 Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, QatarORCID Iconhttps://orcid.org/0000-0002-2984-0252View further author information
ORCID Icon,
Lajos Szabados3 Department of Nuclear Medicine, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarView further author information
,
MZ Sharaf Eldean4 Department of Pathology, Hamad Medical Corporation, Doha, QatarView further author information
,
Sali Alatasi4 Department of Pathology, Hamad Medical Corporation, Doha, QatarView further author information
,
Ruba Y Taha2 Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, QatarView further author information
&
Sarah A Elkourashy2 Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar;5 Weill Cornell Medicine University, Doha, QatarView further author information
 show all
Pages 133-139 | Received 26 Oct 2022, Accepted 17 Feb 2023, Published online: 21 Feb 2023

References

  • Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017;92(6):E114–E117. doi:10.1002/ajh.24720
  • Silva WF, Da, Garibaldi PMM, Rosa LI, et al. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: high treatment toxicity and refractoriness rates - A multicenter cohort study. Leuk Res. 2020;89. doi:10.1016/j.leukres.2019.106287
  • FDA, FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma 2019 Availbale from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma. Accessed February 06 17, 2023 10 06.
  • Stenning SP, Mead GM, Wright D, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13(8):1264–1274. doi:10.1093/annonc/mdf253
  • Mey UJM, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest. 2006;24(6):593–600. doi:10.1080/07357900600814490
  • Coakley D. Denis Burkitt and his contribution to haematology/oncology. Br J Haematol. 2006;135(1):17–25. doi:10.1111/j.1365-2141.2006.06267.x
  • Boxer LM, Dang C. Translocations involving c-myc and c-myc function. Oncogene. 2001;20(40):5595–5610. doi:10.1038/sj.onc.1204595
  • Lap CJ, Nassereddine S, Dunleavy K. Novel biological insights and new developments in management of Burkitt lymphoma and high-grade B-cell lymphoma. Curr Treat Options Oncol. 2021;22(7). doi:10.1007/s11864-021-00857-w
  • Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood. 2021;137(6):743–750. doi:10.1182/blood.2019004099
  • NCCN Guidelines. B-cell lymphomas. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed February 17, 2023.
  • Zhu KY, Song KW, Connors JM, et al. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. Br J Haematol. 2018;181(6):782–790. doi:10.1111/bjh.15262
  • Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519–2529. doi:10.1200/JCO.20.00303
  • Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110(2):616–623. doi:10.1182/blood-2007-01-066704
  • Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–2729. doi:10.1182/blood-2009-02-205500
  • Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578–1586. doi:10.1038/leu.2015.48
  • Australian Prescriber. Polatuzumab vedotin for B-cell lymphoma. Aust Prescr. 2020;43(6):218. doi:10.18773/austprescr.2020.069
  • Malecek MK, Watkins MP, Bartlett NL. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2021;21(7):831–839. doi:10.1080/14712598.2020.1777979
  • Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(2):155–165. doi:10.1200/JCO.19.00172
  • Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019;20(7):998–1010. doi:10.1016/S1470-2045(19)30091-9
  • Diefenbach C, Kahl BS, Banerjee L, et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: primary analysis of the full efficacy population in a Phase Ib/II trial. Blood. 2019;134(Supplement_1):126. doi:10.1182/blood-2019-123669
  • Li D, Lee D, Dere RC, et al. Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019;176(19):3805. doi:10.1111/bph.14784

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.